Fruquintinib or regorafenib? A weighted toxicity score analysis to facilitate better discussions on toxicity and benefits in later-line colorectal cancer treatment

Key Points

• The aim is to evaluate and compare the toxicity profiles of fruquintinib and regorafenib in later-line treatment for colorectal cancer.
• Applied a weighted toxicity score to global phase III trials CORRECT and FRESCO-2.
• Adjusted for toxicity rates in placebo arms to determine net toxicity increase.
• Fruquintinib increased toxicity by 97.8%, while regorafenib increased it by 85.07%.
• Regorafenib was linked to a higher risk of dysphonia, oral mucositis, and weight loss.
• Fruquintinib was associated with a higher risk of hand-foot skin reactions, transaminase elevation, and constipation.